New Indications For Sunovion’s Latuda Mean New Marketing Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
The Japanese pharma gained two more indications for the atypical antipsychotic and hopes to differentiate it by stressing its approval as both a monotherapy and adjunctive therapy to standards of care.